Openbookopenbook
Equity
BIO
+0.0 · +0.00%
USD · NYSE

Bio-Rad Laboratories Inc(BIO) Stock Analysis | Healthcare

USD --+0.00%
Reward54Moderate
Risk34Moderate
75%Data
Balanced
Market Cap:10.17Bn
ⓘ
Reward Rating
54
Moderate
Reward Assessment
75% data coverage
Bottom 50% of stocksView factors
ⓘ
Risk Rating
34
Moderate
Risk Assessment

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on BIO to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
New listing — limited trading history
Fundamental and analyst data are available for BIO, but momentum and volatility metrics will develop as more trading history accumulates (0 trading sessions so far).
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $329.00.

What is Bio-Rad Laboratories Inc?

develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally.

BIO · Verdict

Moderate reward · moderate risk

BIO stands out on cash flow and balance sheet, but watch the valuation signal.

Based on 88% data coverage

BIO · Verdict

What’s working & what to watch

Strengths 3

  • Cash flow81/100

    15% free-cash-flow margin

  • Balance sheet78/100

    Interest covered 21.3×

  • Profitability65/100

    29% net margin · 3% ROE

Watchouts 1

  • Valuation41/100

    P/E 41.7× · PEG 1.19

Model-based scoring. For information only — not financial advice.

What is Bio-Rad Laboratories Inc?

develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The company is listed on the NYSE in USA, operating in the Healthcare sector, with a market capitalisation of 10.17B, and a P/E ratio of 46.3x.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Adequate profitability with some margin variability in recent periods.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Premium valuation reflects strong growth expectations already priced in.

OpenBook Logo Analysis

Reward: Moderate (54)

The scoring profile indicates limited reward potential at this time, with profitability and growth offering the most support. Risk indicators are moderate, consistent with typical market exposure.

For informational purposes only. Not financial advice.

Similar stocks to compare

A short list of Medical Devices names that are close enough in size to make side-by-side comparison useful.

OCPNFLarge Cap / 10.6B market cap
Olympus Corporation
Compare
GKOSLarge Cap / 10.9B market cap
Glaukos Corp
Compare
CHEOFLarge Cap / 11.6B market cap
Cochlear Limited
Compare
Company Information
SectorHealthcare
IndustryMedical Devices
Market Cap10.17B
P/E Ratio46.2887
Dividend YieldN/A
Beta1.047
Insider Activity
12M windowQuiet
Fewer than three real open-market insider trades in the last 12 months. Mechanical activity (option exercises, RSU vests) is excluded from the signal.
openbook

Stock research for UK and US investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.